Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moxetumomab pasudotox
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Moxetumomab pasudotox is a CD22-directed recombinant immunotoxin. It consists of a murine anti-CD22 antibody variable fragment (Fv) fused to a 38 kDa fragment of Pseudomonas exotoxin A (PE38). The drug targets CD22, a surface antigen highly expressed on B-cell malignancies. Upon binding to CD22, the immunotoxin is internalized, and the PE38 moiety catalyzes the ADP-ribosylation of elongation factor 2, leading to the inhibition of protein synthesis and subsequent apoptosis of the target cell. Originally developed by Cambridge Antibody Technology and later by MedImmune (AstraZeneca), it is marketed as Lumoxiti for relapsed or refractory hairy cell leukemia. It has also been investigated in clinical trials for other B-cell malignancies, including chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), and small lymphocytic lymphoma (SLL).
- Brand names
- Lumoxiti
- Other names
- moxetumomab pasudotox-tdfk
02
Targets
EEF2 (Eukaryotic elongation factor 2)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on moxetumomab pasudotox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moxetumomab pasudotox.